Human intestinal epithelial and smooth muscle cells are potent producers of IL-6

Edmond K. Ng  
Saint Louis University

Ninder Panesar  
Saint Louis University

Walter E. Longo  
Saint Louis University

Marc J. Shapiro  
Saint Louis University

Donald L. Kaminski  
Saint Louis University

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Part of the Medicine and Health Sciences Commons

Recommended Citation

Ng, Edmond K.; Panesar, Ninder; Longo, Walter E.; Shapiro, Marc J.; Kaminski, Donald L.; Tolman, Kym C.; and Mazuski, John E., "Human intestinal epithelial and smooth muscle cells are potent producers of IL-6." Mediators of Inflammation, 3-8. (2003). https://digitalcommons.wustl.edu/open_access_pubs/974

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Authors
Edmond K. Ng, Ninder Panesar, Walter E. Longo, Marc J. Shapiro, Donald L. Kaminski, Kym C. Tolman, and John E. Mazuski
**Background**

Interleukin-6 (IL-6), a pluripotent cytokine, has traditionally been considered the product of proinflammatory cells. However, many other cell types have been shown to produce IL-6. Since intestinal inflammation is commonly associated with a vigorous systemic inflammatory response, we hypothesized that intestinal epithelial and smooth muscle cells might contribute to that response by producing IL-6. We therefore studied the capacity of differentiated human intestinal epithelial and smooth muscle cell lines to produce IL-6 in response to various proinflammatory stimuli.

**Materials and methods:** CCL-241, a human intestinal epithelial cell line, and HISM, a human intestinal muscle cell line, were grown to confluency and then treated for 24 h with various concentrations of lipopolysaccharide, *Clostridium difficile* culture extract containing both toxin A and toxin B, recombinant human tumor necrosis factor-alpha (TNF-α), or recombinant human interleukin-1 beta (IL-1β). Supernatants were then collected for IL-6 determination using an enzyme-linked immunosorbent assay. Cell numbers were determined using a Coulter counter. For comparison, parallel studies were performed using phorbol ester-primed U-937 and THP-1 human macrophage cell lines.

**Results:** Both human intestinal epithelial and smooth muscle cells produced IL-6 under basal conditions. In HISM cells, but not in CCL-241 cells, IL-6 release was increased slightly by treatment with *C. difficile* culture extract containing both toxin A and toxin B, and with lipopolysaccharide. In both cell lines, IL-6 production was profoundly stimulated by treatment with IL-1β and less so with TNF-α. Combinations of high-dose TNF-α and IL-1β may have a slightly additive, but not synergistic, effect on IL-6 release. The amount of IL-6 produced by IL-1-stimulated intestinal cell lines was 70-fold higher than that produced by stimulated macrophage cell lines.

**Conclusions:** Both intestinal epithelial and smooth muscle cells demonstrate the ability to release significant amounts of IL-6. The profound response to IL-1β and TNF-α stimulation by both cell lines suggests that human intestinal parenchymal cells, influenced by paracrine mediators liberated from proinflammatory cells, might significantly contribute to the overall systemic inflammatory response by producing IL-6.

**Key words:** Interleukin-6, Interleukin-1, Tumor necrosis factor, Cytokines, Intestine, Epithelium, Smooth muscle, CCL-241, HISM

---

**Introduction**

Interleukin-6 (IL-6) is a pluripotent cytokine that is involved in multiple inflammatory processes. IL-6 acts as a pyrogen, mediates B-cell proliferation and immunoglobulin secretion, and is a primary stimulus for the synthesis of hepatic acute phase proteins. It is also associated with several alterations related to the metabolic stress of the systemic inflammatory state, such as the development of cachexia and anorexia, and stimulation of the hypothalamic–pituitary–adrenal axis by increasing adrenocorticotropic hormone and cortisol release. It is also involved in regulating the secretion of other hormones, including growth hormone and thyroid-stimulating hormone. IL-6 may also have anti-
inflammatory effects since it downregulates interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) secretion, which are known stimulators of IL-6 production.  

Although IL-6 production has often been attributed to proinflammatory cells such as macrophages, it has been demonstrated that IL-6 can be produced by many other cells, such as neurons, glial cells, adipose cells, fibroblasts, osteocytes, hepatocytes, endothelial cells, and a variety of other epithelial cells.  

In fact, IL-6 was initially identified as interferon N produced by fibroblasts and as hepatocyte stimulatory factor produced by a cervical carcinoma cell line.  

Intestinal cells may likewise be an important source of IL-6. IL-6 produced in the intestine may be of significance not only in the local regulation of intestinal immunologic and defense functions, but also could contribute to the development of the systemic inflammatory response. It has been shown that IL-6 production by the intestinal mucosa is upregulated in a number of intestinal disease states, including ischemia/reperfusion (I/R) injury, chronic rejection following small bowel transplantation and inflammatory bowel disease.  

Intestinal cells may likewise be an important source of IL-6. IL-6 produced in the intestine may be of significance not only in the local regulation of intestinal immunologic and defense functions, but also could contribute to the development of the systemic inflammatory response. It has been shown that IL-6 production by the intestinal mucosa is upregulated in a number of intestinal disease states, including ischemia/reperfusion (I/R) injury, chronic rejection following small bowel transplantation and inflammatory bowel disease.  

IL-6 production

At confluency, cultures were treated for 24 h with culture medium containing various concentrations of a Clostridium difficile culture extract (TechLab, Blacksburg, VA, USA), which contains both toxin A and B, lipopolysaccharide (LPS) (Escherichia coli 0111:B4; Difco Laboratories, Detroit, MI, USA), recombinant human IL-1β (R&D Systems, Inc., Minneapolis, MN, USA), or recombinant human TNF-α (R&D Systems, Inc.). Supernatants were removed and centrifuged at 1000 g × 5 min to remove detached cells and were stored at −80°C for subsequent IL-6 determination. Phosphate-buffered saline containing trypsin was added to detach adherent cells, and the cells were centrifuged at 1000 g × 5 min and resuspended in phosphate-buffered saline for determination of cell numbers using a Coulter counter. Sandwich enzyme-linked immunosorbent assay (ELISA) for human IL-6 was performed according to the manufacturer’s directions. This was based on the DuoSet ELISA Development System (R&D Systems, Inc.), which utilizes a mouse anti-human IL-6 capture antibody, a biotinylated goat anti-human IL-6 detection antibody, horseradish peroxidase-conjugated streptavidin, and H2O2/tetramethylbenzidine as the peroxidase substrate. Samples were read using a dual wavelength spectrophotometer (450 nm reading, 540 nm correction), and the amount of IL-6 was calculated using a standard curve prepared with known amounts of purified recombinant human IL-6. According to the specifications provided by the manufacturer, the sensitivity of the assay for IL-6 in culture supernatants was 0.70 pg/ml. No significant cross-reactivity or interference was observed with other cytokines or inhibitors, including leukemia inhibitory factor and interleukin-11. In repetitive testing, intra-assay coefficients of variation ranged from 1.7 to 4.4 and inter-assay coefficients of variation ranged from 2.0 to 3.7.

Statistical methods

Measurements represent mean ± standard error of the mean. The amounts of IL-6 produced under different conditions were compared within each cell line using a paired t-test with Bonferroni correction for multiple
comparisons with control values. The unpaired t-test was utilized for comparisons between cell lines.

Results

CCL-241 release of IL-6 following treatment with C. difficile toxin, LPS, IL-1β, and TNF-α

The human intestinal epithelial cell line released detectable amounts of IL-6 into the culture medium under basal conditions (Table 1). Neither C. difficile toxins nor LPS stimulated IL-6 release. Both IL-1β and TNF-α stimulated IL-6 release in a dose-dependent manner. TNF-α produced a 10-fold increase in IL-6 release, while IL-1β elicited a 150-fold increase in IL-6 release. Cells stimulated with high concentrations of both IL-1β and TNF-α produced greater amounts of IL-6 than those stimulated with either cytokine alone, although this was not statistically significant (Table 2). However, combinations of IL-1β and TNF-α at lower concentrations (2.0 U/ml and 1 ng/ml, respectively) elicited a seven-fold increase in IL-6 production compared with that produced by either cytokine alone.

HISM release of IL-6 following treatment with C. difficile toxin, LPS, IL-1β, and TNF-α

The human intestinal smooth muscle cell released 14-fold higher amounts of IL-6 under basal conditions than did the CCL-241 cells (Table 1). C. difficile toxins and LPS stimulated slight increases in IL-6 release, although these did not reach statistical significance. As with CCL-241 cells, both TNF-α and IL-1β stimulated IL-6 release in a dose-dependent manner. TNF-α increased IL-6 release approximately four-fold but IL-1β elicited a greater than 10-fold increase in IL-6 release. Combinations of high-dose IL-1β and TNF-α also resulted in a slight augmentation of IL-6 release compared with that of IL-1β alone, although these were not statistically significant (Table 2). Additionally, combinations of lower concentrations of IL-1β and TNF-α (2.0 U/ml and 1 ng/ml, respectively) did not give rise to increased IL-6 release compared with that produced by either cytokine alone.

Macrophage release of IL-6 following treatment with C. difficile toxin, LPS, IL-1β, and TNF-α

Under basal conditions, U-937 cells released small amounts of IL-6. However, the amounts of IL-6 produced by THP-1 cells were insufficient for detection using the ELISA. C. difficile toxins, IL-1β, and TNF-α elicited no further stimulation of IL-6 in U-937 cells. LPS, however, increased IL-6 production 50-fold in U-937 cells and stimulated THP-1 cells to produce detectable levels of IL-6 (Table 2). It is notable that the maximum amount of IL-6 produced by these macrophage cell lines was 100-fold less than that produced by maximally stimulated CCL-241 or HISM cells.

Table 1. Effects of various stimuli on IL-6 production by CCL-241 cells, and on IL-6 release by HISM cells and by macrophage cell lines

<table>
<thead>
<tr>
<th>Stimulator</th>
<th>IL-6 production by CCL-241 cells (pg/1000 cells)</th>
<th>IL-6 release by HISM cells (pg/1000 cells)</th>
<th>U-937 (pg/1000 cells)</th>
<th>THP-1 (pg/1000 cells)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>10 ± 1</td>
<td></td>
<td>0.5 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>CdT (1:2 x 10⁶)</td>
<td>9 ± 8</td>
<td>140 ± 70</td>
<td>0.5 ± 0.4</td>
<td>N.D.</td>
</tr>
<tr>
<td>CdT (1:2 x 10⁵)</td>
<td>7 ± 6</td>
<td>180 ± 85</td>
<td>0.5 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>CdT (1:2 x 10⁴)</td>
<td>5 ± 5</td>
<td>180 ± 80</td>
<td>0.5 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>CdT (1:2 x 10³)</td>
<td>4 ± 4</td>
<td>270 ± 170</td>
<td>0.5 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>CdT (1:2 x 10²)</td>
<td>11 ± 15</td>
<td>540 ± 490</td>
<td>0.6 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>LPS (0.001 μg/ml)</td>
<td>10 ± 10</td>
<td>165 ± 75</td>
<td>2 ± 1</td>
<td>0.1 ± 0.0</td>
</tr>
<tr>
<td>LPS (0.01 μg/ml)</td>
<td>8 ± 3</td>
<td>160 ± 70</td>
<td>6 ± 2*</td>
<td>1 ± 0.2</td>
</tr>
<tr>
<td>LPS (0.1 μg/ml)</td>
<td>9 ± 3</td>
<td>190 ± 90</td>
<td>14 ± 7**</td>
<td>5 ± 1</td>
</tr>
<tr>
<td>LPS (1.0 μg/ml)</td>
<td>10 ± 5</td>
<td>250 ± 160</td>
<td>23 ± 12</td>
<td>10 ± 4</td>
</tr>
<tr>
<td>LPS (10 μg/ml)</td>
<td>9 ± 3</td>
<td>230 ± 116</td>
<td>24 ± 11*</td>
<td>11 ± 4</td>
</tr>
<tr>
<td>IL-1β (0.02 U/ml)</td>
<td>10 ± 9</td>
<td>170 ± 90</td>
<td>0.5 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>IL-1β (0.2 U/ml)</td>
<td>20 ± 13*</td>
<td>190 ± 100</td>
<td>0.5 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>IL-1β (2.0 U/ml)</td>
<td>450 ± 150*</td>
<td>270 ± 125</td>
<td>0.5 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>IL-1β (20 U/ml)</td>
<td>1060 ± 580*</td>
<td>1060 ± 580*</td>
<td>0.5 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>IL-1β (200 U/ml)</td>
<td>1300 ± 740*</td>
<td>2500 ± 1100*</td>
<td>0.5 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>IL-1β (2000 U/ml)</td>
<td>1500 ± 950*</td>
<td>2380 ± 1200*</td>
<td>0.6 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>TNF-α (0.1 ng/ml)</td>
<td>27 ± 20</td>
<td>230 ± 164</td>
<td>0.5 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>TNF-α (1.0 ng/ml)</td>
<td>33 ± 25*</td>
<td>382 ± 226*</td>
<td>0.5 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>TNF-α (10 ng/ml)</td>
<td>70 ± 41*</td>
<td>481 ± 270*</td>
<td>0.5 ± 0.3</td>
<td>N.D.</td>
</tr>
<tr>
<td>TNF-α (100 ng/ml)</td>
<td>106 ± 70*</td>
<td>560 ± 385*</td>
<td>0.8 ± 0.2</td>
<td>N.D.</td>
</tr>
</tbody>
</table>

n = 6 experiments/condition, *p < 0.05 versus control (with Bonferroni correction for multiple comparisons). CdT, C. difficile culture extract containing both toxin A and toxin B; N.D., not determined.
Table 2. Effect of combined stimuli on IL-6 production

<table>
<thead>
<tr>
<th>Stimulator</th>
<th>CCL-241 cells&lt;sup&gt;a&lt;/sup&gt;</th>
<th>HISM cells&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>3 ± 2</td>
<td>130 ± 50</td>
</tr>
<tr>
<td>LPS (10 µg/ml)</td>
<td>3 ± 1</td>
<td>223 ± 90</td>
</tr>
<tr>
<td>IL-1β (2.0 U/ml)</td>
<td>32 ± 14</td>
<td>250 ± 95</td>
</tr>
<tr>
<td>TNF-α (1.0 ng/ml)</td>
<td>33 ± 8</td>
<td>480 ± 220</td>
</tr>
<tr>
<td>LPS and IL-1β (200 U/ml)</td>
<td>935 ± 723</td>
<td>1335 ± 550</td>
</tr>
<tr>
<td>LPS and TNF-α (100 ng/ml)</td>
<td>166 ± 102</td>
<td>1000 ± 585</td>
</tr>
<tr>
<td>TNF-α (1.0 ng/ml) and IL-1β (200 U/ml)</td>
<td>859 ± 343</td>
<td>2500 ± 990</td>
</tr>
<tr>
<td>TNF-α (100 ng/ml) and IL-1β (2.0 U/ml)</td>
<td>391 ± 198</td>
<td>1100 ± 740</td>
</tr>
<tr>
<td>TNF-α (1.0 ng/ml) and IL-1β (2 U/ml)</td>
<td>221 ± 113*</td>
<td>525 ± 260</td>
</tr>
<tr>
<td>TNF-α (100 ng/ml) and IL-1β (200 U/ml)</td>
<td>1251 ± 511</td>
<td>2470 ± 1070</td>
</tr>
</tbody>
</table>

<sup>a</sup>n = 4 experiments/condition, *p < 0.05 versus IL-1β (2.0 U/ml) versus TNF-α (1.0 ng/ml) (with Bonferroni correction for multiple comparisons).<sup>b</sup>n = 6 experiments/condition, no values reached statistical significance of p < 0.05 versus appropriate control (with Bonferroni correction for multiple comparisons).

Discussion

IL-6 was originally identified on the basis of many different biologic activities and was variously called interferon-β2, B-cell stimulatory factor 2, 26 kDa protein, hybridroma/plasmacytoma growth factor, hepatocyte stimulating factor, and monocyte granulocyte inducer type 2. IL-6 and other cytokines that bind to the cellular IL-6 receptor or the soluble IL-6 receptor or the soluble IL-6 receptor, either separately or in combination, have biologic activities and was variously called interferon-β2, B-cell stimulatory factor 2, 26 kDa protein, hybridoma/plasmacytoma growth factor, hepatocyte stimulating factor, and monocyte granulocyte inducer type 2. IL-6 and other cytokines that bind to the cellular IL-6 receptor or the soluble IL-6 receptor have been implicated in the pathogenesis of a broad spectrum of disease processes, including Castleman’s Syndrome and multiple myeloma, Kaposi’s sarcoma-associated herpes virus-8 infection, thrombosis in myocardial infarction, myocardial cell hypertrophy in congestive heart failure, osteoporosis and other diseases with increased osteoclastic bone resorption, rheumatoid arthritis, systemic lupus erythematosus, and cancer-related anorexia/cachexia syndrome.

In the gut, IL-6 has been linked to I/R injury, chronic rejection following small bowel transplantation, and both Crohn’s disease and ulcerative colitis. In a rat intestinal I/R model, accumulation of IL-6 mRNA in the mucosa and muscularis externa was shown to precede immunohistochemical evidence of cellular I/R injury. In rat small intestinal transplants, in situ hybridization demonstrated the presence of increased mucosal and muscularis externa IL-6 mRNA in experimental chronic rejection.

A number of clinical reports have also suggested a role of IL-6 in the pathogenesis of inflammatory bowel disease. Both patients with Crohn’s disease and with ulcerative colitis have elevated amounts of IL-6 in the serum, circulating and resident proinflammatory cells, and in mucosal samples. While a number of studies have demonstrated increases in IL-6 production by mucosal biopsies, there has been little consensus with regard to the primary cellular source of IL-6. A few studies utilizing in situ hybridization for IL-6 mRNA or measuring IL-6 in Percoll gradient isolated intestinal epithelial and lamina propria mononuclear cells have suggested that the primary source of IL-6 is from the lamina propria mononuclear cells.

However, in one of these studies, in situ hybridization demonstrated greater amounts of IL-6 message in the mucosa than in the lamina propria. Additionally, a different study using in situ hybridization demonstrated equally prominent IL-6 expression in both areas. Finally, a study detecting IL-6 protein using immunohistochemistry/fluorescence demonstrated that IL-6 was predominantly present in the enterocytes and colonocytes of patients with inflammatory bowel disease. Therefore, it remains unclear whether one or both of these cell types are the most important contributors to IL-6 production during intestinal inflammation.

Although normal intestinal epithelial cells have been shown to express IL-6 receptors and to respond to IL-6, few studies have focused on the production of IL-6 by pure intestinal epithelial cell lines. Goodrich and McGee have demonstrated that IL-6 can be produced by cultured rat intestinal cells, and Strong et al. have shown that IL-6 mRNA is produced by primary cultures of human intestinal cells. However, Fayyazi et al. stated that IL-6 mRNA was undetectable in human colonic epithelium. There are also some studies suggesting that intestinal smooth muscle cells produce IL-6. In the rat intestine, and in cultured rat intestinal smooth muscle cells, IL-1β and TNF-α were found to stimulate IL-6 mRNA and IL-6 production. Possible IL-6 production by the intestinal smooth muscle cells could therefore correspond to the findings of significant IL-6 localization in the muscularis externa in animal models of I/R injury and chronic rejection. In our studies, the representative human cell lines, CCL-241 and HISM, were potent producers of IL-6.
when stimulated by TNF-α, and particularly by IL-1β. Our findings correspond to other studies that have shown these cytokines to be the primary stimulators of IL-6 production from other cell lines.\(^6\)\(^{15}\) IL-1β and TNF-α may have had slight additive effects on the amount of IL-6 production, although this effect was not dramatic. The failure to demonstrate greater responses to combinations of these cytokines may indicate that both agents act through a common final mechanism to stimulate IL-6 production.

The amount of IL-6 produced by the epithelial and smooth muscle cells was substantially greater than that produced by the macrophage cells. In addition, the stimuli eliciting IL-6 release were quite distinct; LPS was the most potent stimulator of macrophage IL-6 release, but it only slightly stimulated IL-6 release by intestinal smooth muscle cells and had no effect on intestinal epithelial cells. However, it might be anticipated that intestinal epithelial cells should not respond to LPS since these cells might normally be exposed to luminal endotoxin on a constant basis. Exposure to C. difficile toxins and LPS did seem to produce a trend towards increased IL-6 production by the intestinal smooth muscles cells. This seems reasonable since these cells would not normally be exposed to luminal toxins \textit{in vivo}.

Overall, the findings from these experiments clearly demonstrate that intestinal epithelial and smooth muscle cells have the capacity to produce IL-6. It can be hypothesized that IL-6 production by these cells plays a role in the local and systemic inflammatory processes during intestinal diseases. An initiating factor (such as expression of the luminal proinflammatory cytokines in Crohn's disease) could stimulate IL-1β and TNF-α production by the resident macrophages and other proinflammatory cells in the bowel wall. These cytokines could then stimulate intestinal epithelial cells and intestinal smooth muscle cells to produce IL-6. This IL-6, acting in a paracrine fashion, could modulate the local immunologic and inflammatory responses in the bowel wall. In addition, the IL-6 produced could also act in an endocrine fashion to augment the systemic inflammatory reaction. Thus, the resident parenchymal and mesenchymal cells of the bowel through their elaboration of mediators, such as IL-6, may be of importance in understanding the pathogenesis of intestinal diseases.

Acknowledgements. Partial funding provided by a Surgical Infection Society Resident Research Fellowship Grant, 1999--2000. Supported in part by a fellowship to Dr. Ng from the Surgical Infection Society.

References


Manelagac SC. The role of IL-6 type cytokines and their receptors in disease. Annu NY Acad Sci 1998; 840: 194--203.


Received 21 August 2002
Accepted 29 October 2002